• E-Paper
  • Sign In
  • UAE
    • Transport
    • Crime
    • Education
    • Legal
    • Weather
    • Emergencies
    • Jobs
    • KT Engage
    • UAE Holidays
    • Banking in UAE
    • Visa & Immigration
    • Living in the UAE
    • Schools & Parents
    • Ramadan 2026
    • Global Indians
  • WORLD
    • GCC
    • Asia
    • Supplements
  • BUSINESS
    • Galadari Brothers
    • Investing
    • Real Estate
    • Energy
    • Aviation
    • Leadership Lists
    • KT Network
  • TECH
    • BTR
  • LIFE
    • Sports
    • Entertainment
    • Food
    • Travel
    • Beauty & Health
    • Fashion
    • KT LUXE
  • KT EVENTS
    • KT UniExpo -10th Edition
    • FWF Summit
    • TRIBE-4th Edition
    • NAFA-8th Edition
  • SUBSCRIPTIONS
  • WEATHER
  • Download our Mobile App

    • iOS
    • Android

VOICE OF THE UAE. SINCE 1978

  • World
  • GCC
  • Asia
  • Supplements
  • Home
  • World
  • Asia

Cipla to sell weight-loss drug Mounjaro's active ingredient in India

The Indian drugmaker has signed an agreement with Eli Lilly to sell tirzepatide in the country

  • Published: Thu 23 Oct 2025, 2:36 PM

    • By
    • Reuters
    • Follow on Google
    • Follow on WhatsApp
    • Follow on Telegram

Vials of Eli Lilly's Mounjaro, a tirzepatide injection drug used for treating type 2 diabetes and weight loss. Photo: Reuters file

Indian drugmaker Cipla signed an agreement with Eli Lilly to sell tirzepatide, the active ingredient in the US company's blockbuster weight-loss drug Mounjaro, in India, the companies said on Thursday.

Advertising
Advertising

ALSO READ:

  • Pfizer to buy weight-loss drug developer Metsera in $7.3 billion deal
  • WHO backs weight-loss drugs, urges cheap generic versions
  • India

Download Our Mobile app

  • iOS
  • Android

Follow Us

    • UAE
    • World
    • Business
    • Tech
    • Life
    • About Us
    • Advertise With Us
    • Contact Us
    • Privacy Notice
    • Sitemap

    ©2026 Galadari Printing and Publishing LLC. All rights reserved.